
NITI Aayog recommends creation of chemical hubs, port clusters to boost manufacturing
In a report titled Chemical Industry: Powering India's Participation in
Global Value Chains
, the policy think tank said the country is targeting $1 trillion in chemical output by 2040.
GVC share, job creation, and trade deficit
According to the report, India aims to increase its share in Global Value Chains (GVC) from 3.5 per cent in 2023 to 5–6 per cent by 2040, with the potential to create 700,000 additional jobs by 2030.
India's current share in global chemical value chains and a
chemical trade deficit
of USD 31 billion in 2023 reflect its dependence on imported feedstock and specialty chemicals.
'Targeted reforms encompassing a range of fiscal and non-fiscal interventions will enable India to reach a $1 trillion chemical sector and achieve a 12 per cent GVC share by 2040,' the report stated.
Port, environmental, and policy interventions
The report called for the formation of an empowered committee at the Central level and the creation of a chemical fund with a budgetary outlay for shared infrastructure and viability gap funding. It also recommended that an administrative body manage each chemical hub.
It proposed a Chemical Committee for ports to advise on and address infrastructure gaps in chemical trade, along with the development of eight port clusters with high potential.
Other suggestions include incentivising incremental production of chemicals based on import bills, export potential, single-country dependence, and end-market needs.
On regulatory aspects, the report recommended fast-tracking environmental clearance. 'Simplify and fast-track EC clearance process through setting up an audit committee under DPIIT to monitor timelines and compliance, and publish periodic reports and give more autonomy to EAC,' it said.
The report also noted that India could consider Free Trade Agreements (FTAs) with provisions specific to the chemicals industry, including tariff quotas and selective duty exemptions on raw materials and petrochemical feedstocks.
Challenges identified
India's chemical sector faces structural challenges, including reliance on imported feedstock, infrastructure gaps, outdated industrial clusters, and logistics costs. These factors have contributed to cost disadvantages compared to other countries.
The report highlighted that India's
investment in R&D
is 0.7 per cent, lower than the global average of 2.3 per cent, affecting innovation in high-value chemicals.
It also cited regulatory delays, particularly in environmental clearances, and a shortfall of 30 per cent in skilled professionals in areas like green chemistry, nanotechnology, and process safety.
'By addressing the existing challenges and leveraging the proposed interventions, India can enhance its competitiveness, attract investments, and build a chemical sector capable of leading the global value chain,' the report said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
16 minutes ago
- Economic Times
Regulatory gray area makes investing in LVMH, BP tough For Indian retail
The world's largest sovereign fund, Norges Bank, credited European stocks for the gains this year in a rare episode in recent years. But Indian retail investors, who on paper can invest lakhs of USD overseas, are missing the European bus as an unreasoned regulatory cap holds back mutual funds from launching schemes that could benefit from what appears to be a continental renaissance. The MSCI Europe Index has soared 22% since January, easily


Hindustan Times
16 minutes ago
- Hindustan Times
Man accused of selling fake meds denied bail
A Delhi court on Monday denied anticipatory bail to a man accused of supplying fake Ozempic medicines to several foreign companies, observing that such instances threaten the reputation of India's pharmaceutical industry and endanger public health. (Getty Images/iStockphoto) Ozempic is used to cure Type-2 Diabetes and is an anti-obesity medication used for long-term weight management. The order was passed by additional sessions judge Saurabh Partap Singh Laler of Patiala House Court. The court was deciding on an anticipatory bail plea moved by Vicky Ramancha, who has been accused of criminal conspiracy and cheating a foreign firm by supplying them counterfeit pharmaceutical drugs, specifically Ozempic. A case was lodged against Ramancha by the Delhi Police Economic Offences Wing (EOW). The court said, 'The discretionary remedy of anticipatory bail cannot be granted in circumstances where allegations involve grave offences against public health and safety, international ramifications threaten India's pharmaceutical industry reputation…grant of bail would undermine public confidence in criminal justice system.' The prosecution claimed that the accused was part of a trans-national fraud operation that purportedly caused financial losses exceeding USD 18.8 million to the complainant company. The police further claimed that investigation revealed a systematic pattern of criminal misconduct wherein false representation was created by the accused of having legitimate pharmaceutical supply chains and government connections in India. Police said that false certificates were notarised by Patiala House Courts itself to create a false impression and build trust for larger transactions. To be sure, the case also attracted the attention of US federal authorities, wherein the complainant company received subpoenas (notice to appear in court or produce evidence) from the US Department of Justice regarding potential violations of federal criminal laws, including importation and misbranded drugs. Advocate Yagyesh Kumar, appearing for the accused, argued that the case did not fall within the territorial jurisdiction of the court as the transaction took place outside the country and a commercial arbitration case was already ongoing at London Court of International Arbitration (LCIA). He further added that the fake medicines were due to genuine business difficulties rather than with a criminal intent.


India Today
31 minutes ago
- India Today
Trump threatens lawsuit against Fed chair Powell over costly renovations
US President Donald Trump has intensified his criticism of Federal Reserve Chair Jerome Powell, saying he is considering allowing a 'major lawsuit' over Powell's handling of costly renovations at the Fed's Washington, DC, a Truth Social post on Tuesday, Trump accused Powell of overseeing 'grossly incompetent' management of the project, which he claimed has soared to USD 3 billion from what should have been a USD 50 million fix-up. advertisementWhite House press secretary Karoline Leavitt confirmed the president is considering legal action but offered no further details. So far, the Fed has not issued any response over the matter. The renovations, involving two historic buildings, were originally budgeted at USD 1.9 billion but are now projected to cost USD 2.4 billion, according to Fed documents. The central bank attributes the overruns to higher labor and materials costs, asbestos abatement, and other unforeseen has repeatedly pressured Powell to slash interest rates, arguing that lower borrowing costs would save the US billions. The Fed, which raised rates in 2022 and cut them several times in 2024, has so far held them steady in 2025 despite Trump's demands. Powell has previously pushed back, including during a recent meeting with Trump at the construction site.A Supreme Court ruling earlier this year reaffirmed that the Fed chair cannot be removed by the president over policy disagreements, highlighting the central bank's independence.- EndsTune InMust Watch